NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, TO US PERSONS OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO WOULD BE UNLAWFUL. THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER TO SELL OR ISSUE, OR ANY SOLICITATION OF ANY OFFER TO PURCHASE, SUBSCRIBE FOR OR OTHERWISE ACQUIRE, ANY INVESTMENTS IN ANY JURISDICTION
22 November 2024
GEIGER COUNTER LIMITED
("GCL" OR THE "COMPANY")
Publication of Prospectus
The Board of the Company today announces the publication of a prospectus (the "Prospectus") in relation to the admission of its ordinary shares to the to the Official List of the FCA and to trading on the London Stock Exchange's Main Market (the "Admission"), the 2025 Subscription Rights Issue and the Placing Programme. The Board has also approved the cancellation of the listing of the Company's ordinary shares on The International Stock Exchange (the "TISE Cancellation"). Application has been made for the admission of the Company's ordinary shares to the Official List of the Financial Conduct Authority and to trading on London Stock Exchange plc's Main Market for listed securities with Admission and the TISE Cancellation expected to become effective on or around 28 November 2024.
A copy of the Prospectus will be submitted to the National Storage Mechanism and will be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism shortly as well as on the Company's website at https://ncim.co.uk/geiger-counter-ltd/.
Unless otherwise defined, the terms used in this announcement shall have the same meaning as set out in the Prospectus.
Enquiries
| Manulife | CQS | Craig Cleland | T: +44 (0) 20 7201 5368
|
| Cavendish Capital Markets Limited | Tunga Chigovanyika (Corporate Finance)
| T: +44 (0) 20 7397 1915
|
|
| Daniel Balabanoff / Pauline Tribe (Sales)
| T: +44 (0) 20 7220 0517 |
| R&H Fund Services (Jersey) Limited | Jane De Barros | T :+44 (0) 1534 825 259 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
